# Intellia appoints Jing L. Marantz as Chief Medical Officer, effective October 26

Canonical page: https://technooptimist.io/stories/intellia-appoints-jing-l-marantz-as-chief-medical-officer-effective-8104aa75
Date: 13 Oct 2026
About: [Intellia Therapeutics](https://technooptimist.io/companies/intellia-therapeutics.md)
Original source: https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-appoints-jing-marantz-cmo

Intellia Therapeutics has named Jing L. Marantz, M.D., Ph.D., Executive Vice President and Chief Medical Officer, effective October 26, 2026. She will lead the company's translational, development, regulatory and medical affairs functions. She most recently was CMO at Scholar Rock, where she oversaw the U.S. approval of ISEMBYLD.

## Key facts

- Her remit covers translational, development, regulatory and medical affairs
- Before Scholar Rock she held senior leadership roles at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD and Millennium Pharmaceuticals
- She also sits on the board of Arcturus Therapeutics

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.